Literature DB >> 34969939

Association of β-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.

Han Soo Yoo1, Seun Jeon1, Enrica Cavedo1, MinJin Ko1, Mijin Yun1, Phil Hyu Lee1, Young H Sohn1, Michel J Grothe1, Stefan Teipel1, Harald Hampel1, Alan C Evans1, Byoung Seok Ye2.   

Abstract

OBJECTIVE: Cholinergic degeneration and β-amyloid contribute to brain atrophy and cognitive dysfunction in Alzheimer disease (AD) and Lewy body disease (LBD), but their relationship has not been comparatively evaluated.
METHODS: In this cross-sectional study, we recruited 28 normal controls (NC), 55 patients with AD mild cognitive impairment (MCI), 34 patients with AD dementia, 28 patients with LBD MCI, and 51 patients with LBD dementia. Participants underwent cognitive evaluation, brain MRI to measure the basal forebrain (BF) volume and global cortical thickness (CTh), and 18F-florbetaben (FBB) PET to measure the standardized uptake value ratio (SUVR). Using general linear models and path analyses, we evaluated the association of FBB-SUVR and BF volume with CTh or cognitive dysfunction in the AD spectrum (AD and NC) and LBD spectrum (LBD and NC), respectively. Covariates included age, sex, education, deep and periventricular white matter hyperintensities, intracranial volume, hypertension, diabetes, and hyperlipidemia.
RESULTS: BF volume mediated the association between FBB-SUVR and CTh in both the AD and LBD spectra, while FBB-SUVR was associated with CTh independently of BF volume only in the LBD spectrum. Significant correlation between voxel-wise FBB-SUVR and CTh was observed only in the LBD group. FBB-SUVR was independently associated with widespread cognitive dysfunction in both the AD and LBD spectra, especially in the memory domain (standardized beta [B] for AD spectrum = -0.60, B for LBD spectrum = -0.33). In the AD spectrum, BF volume was associated with memory dysfunction (B = 0.18), and CTh was associated with language (B = 0.21) and executive (B = 0.23) dysfunction. In the LBD spectrum, however, BF volume and CTh were independently associated with widespread cognitive dysfunction.
CONCLUSIONS: There is a common β-amyloid-related degenerative mechanism with or without the mediation of BF in the AD and LBD spectra, while the association of BF atrophy with cognitive dysfunction is more profound and there is localized β-amyloid-cortical atrophy interaction in the LBD spectrum.
© 2021 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34969939      PMCID: PMC8901177          DOI: 10.1212/WNL.0000000000013277

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  49 in total

1.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

2.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.

Authors:  Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo
Journal:  Ann Neurol       Date:  2016-07-08       Impact factor: 10.422

3.  A voxel-based morphometric study of ageing in 465 normal adult human brains.

Authors:  C D Good; I S Johnsrude; J Ashburner; R N Henson; K J Friston; R S Frackowiak
Journal:  Neuroimage       Date:  2001-07       Impact factor: 6.556

4.  Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients.

Authors:  Hyun-Jung Ahn; Juhee Chin; Aram Park; Byung Hwa Lee; Mee Kyung Suh; Sang Won Seo; Duk L Na
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

5.  Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies.

Authors:  Lidia Sarro; Matthew L Senjem; Emily S Lundt; Scott A Przybelski; Timothy G Lesnick; Jonathan Graff-Radford; Bradley F Boeve; Val J Lowe; Tanis J Ferman; David S Knopman; Giancarlo Comi; Massimo Filippi; Ronald C Petersen; Clifford R Jack; Kejal Kantarci
Journal:  Brain       Date:  2016-07-24       Impact factor: 13.501

Review 6.  Pathology and neurotransmitter abnormalities of dementia with Lewy bodies.

Authors:  John E Duda
Journal:  Dement Geriatr Cogn Disord       Date:  2004       Impact factor: 2.959

7.  Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET.

Authors:  Renaud La Joie; Adrienne V Visani; Suzanne L Baker; Jesse A Brown; Viktoriya Bourakova; Jungho Cha; Kiran Chaudhary; Lauren Edwards; Leonardo Iaccarino; Mustafa Janabi; Orit H Lesman-Segev; Zachary A Miller; David C Perry; James P O'Neil; Julie Pham; Julio C Rojas; Howard J Rosen; William W Seeley; Richard M Tsai; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Sci Transl Med       Date:  2020-01-01       Impact factor: 17.956

8.  Amyloid-β-related and unrelated cortical thinning in dementia with Lewy bodies.

Authors:  Young-Gun Lee; Seun Jeon; Han Soo Yoo; Seok Jong Chung; Seung-Koo Lee; Phil Hyu Lee; Young Ho Sohn; Mijin Yun; Alan C Evans; Byoung Seok Ye
Journal:  Neurobiol Aging       Date:  2018-08-11       Impact factor: 4.673

9.  Dissociation of Tau Deposits and Brain Atrophy in Early Alzheimer's Disease: A Combined Positron Emission Tomography/Magnetic Resonance Imaging Study.

Authors:  Yoko Shigemoto; Daichi Sone; Etsuko Imabayashi; Norihide Maikusa; Nobuyuki Okamura; Shozo Furumoto; Yukitsuka Kudo; Masayo Ogawa; Harumasa Takano; Yuma Yokoi; Masuhiro Sakata; Tadashi Tsukamoto; Koichi Kato; Noriko Sato; Hiroshi Matsuda
Journal:  Front Aging Neurosci       Date:  2018-07-18       Impact factor: 5.750

Review 10.  Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more
  2 in total

Review 1.  Tau proteins in blood as biomarkers of Alzheimer's disease and other proteinopathies.

Authors:  Federico Verde
Journal:  J Neural Transm (Vienna)       Date:  2022-02-17       Impact factor: 3.575

2.  Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.

Authors:  Ying Jiang; John J Alam; Stephen N Gomperts; Paul Maruff; Afina W Lemstra; Ursula A Germann; Philip H Stavrides; Sandipkumar Darji; Sandeep Malampati; James Peddy; Cynthia Bleiwas; Monika Pawlik; Anna Pensalfini; Dun-Sheng Yang; Shivakumar Subbanna; Balapal S Basavarajappa; John F Smiley; Amanda Gardner; Kelly Blackburn; Hui-May Chu; Niels D Prins; Charlotte E Teunissen; John E Harrison; Philip Scheltens; Ralph A Nixon
Journal:  Nat Commun       Date:  2022-09-21       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.